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ABSTRACT
Classical swine fever (CSF) is a viral infectious disease mainly affecting wild boars
and captive pigs. Being highly contagious and lethal, an outbreak causes both tremendous
direct economic loss and financial burden before a new round of production. The disease
has been long endemic in Asia, Central and South America, Africa and some regions in
Europe, while many developed countries including the US, Canada, Australia, New
Zealand and several members of the European Union have taken strict measures to
successfully eradicate it. Vaccines currently available can protect pigs throughout their
economic life, however, countries without endemics choose to not them for the concern
of stamping out policy since no sophisticated marker vaccines together with companion
tests fulfilling DIVA (differentiation of infected from vaccinated animals) criterion are
approved yet.
The causative agent is classical swine fever virus (CSFV), under the family
Flaviviridae and genus Pestivirus. Viral particle is 40-60 nm in diameter, containing
icosahedral nucleocapsid and its genome is single stranded positive-sense RNA (~12.5
kb). Lipid bilayer envelope is anchored with three viral proteins: Erns, E1 and E2 among
which E2 is the most immunogenic and induces strong antibody response in hosts.
Several approaches are currently available for CSFV diagnosis: (i) detection of
CSFV, and (ii) detection of CSFV specific antibody. Identifying the existence of virus
particle or necropsy is labor-intensive and not suitable for high throughput screening in
the event of which ELISA-based test is preferred for detecting virus specific antibodies.
ix

This research project is aimed at modifying a widely used commercial ELISA to serve as
a companion test for a previous marker vaccine candidate with the intention of
discriminating CSFV naturally infected from vaccinated pigs.
Baculovirus/insect cell protein expression system has been long practiced and proved
an effective way to biosynthesize recombinant proteins. Sequences encoding foreign
protein can be easily incorporated into recombinant baculoviruses using commercially
available kits. In this research, a recombinant baculovirus was constructed and used to
infect Sf9 cells to synthesize genetically modified viral envelope glycoprotein E2 which
plays a key role in the ELISA-based test.

x

CHPATER 1
INTRODUCTION

1

1.1 CSF: Introduction
The first record of hog cholera which is now known as classical swine fever was
presumably in 1833 in Ohio, USA, one of many outbreaks during that time as claimed by
Hanson (Hanson, 1957). However, the disease has been suspected to be transmitted from
Europe since a similar one was documented in 1822, France (Birch 1992; cited byCole et
al., 1884). Falling into the OIE (World Organization for Animal Health) list, it is required
that any infection cases be reported so that elimination of pigs and other measures can be
taken to control spread. The disease can almost be considered the most economically
significant one affecting pig industry, leading to tremendous loss once an outbreak is
confirmed. Despite being widespread in both Europe and the US, till the 1860s, many
developed countries including America, Canada, Australia, New Zealand and some
members of the European Union have successfully eradicated the endemic of CSF with
strict actions such as the stamping out policy. However, the disease is still a big concern
in many parts of Asia, Central and South America, Africa and several countries in
Europe. Therefore, risk of transmission to and causing outbreaks in nations without such
endemic disease does exist since those countries do not adapt routine vaccines against
CSFV.

1.2 Disease
Classical swine fever is mostly seen transmitted oronasally, while transmission via
fomite or skin wound is possible. Transplacental infection was also reported (Oirschot &
2

Terpstra, 1977). Many factors including viral virulence, age and breed of infected swine,
etc., (Depner et al., 1997; Moennig & Plagemann, 1992; Van Oirschot, 1999) contribute to
severity and disease related signs which are characteristically exhibited by pyrexia,
hemorrhage of the outer skin and mucosae and central nervous system disorders (Moennig,
2000). Mortality rate among young pigs is especially high, being around 90%-100% and
death can occur two to three weeks after initiation of acute infection. Prenatal infection of
sows may lead to abortion, stillbirth, malformations and persistently viremic piglets
(Meyer, Liess, Hermanns, & Trautwein, 1980).
Density of pig population is largely related to the risk of disease transmission and a
potential outbreak. Some regions adapt the intensification pattern of producing pigs to a
large-scale while others prefer to raise them in small-sized farms. Despite the high
concentration in mass pig production, it is relatively easier to regulate and perform quality
control. Pigs in small private farms may be confronted with less risk of cross infection, but
the general management and surveillance of these farms are more difficult to conduct.
Infected wild boars or feral pigs can, if having contact with, transmit virus to domestic pigs
both in a direct and indirect (fomite transmission) way.

1.3 Disease Control
Effective control of CSFV requires establishment of epidemiological work, e.g.
investigation and tracking of each outbreak and performing virus isolate typing (GreiserWilke, Depner, Fritzemeier, Haas, & Moennig, 1998; Greiser-Wilke, Zimmermann,
3

Fritzemeier, Floegel, & Moennig, 2000; Paton, McGoldrick, Greiser-Wilke, et al., 2000).
Apart from a well-developed understanding of epidemiological situation, an accurate and
efficient laboratory diagnosis is indispensable. Modern molecular approaches have been
utilized for screening from two perspectives: (i) detection of virus, and (ii) detection of
virus specific antibodies.
To detect the presence of viral particles, isolation of virus in cell culture is still the
‘gold standard’. Ongoing viremia is required for the isolation of CSFV from animal spleen,
tonsils, lymph nodes, parotid glands and kidneys (Anonymous, 1980, 1996). Isolated virus
is then grown in susceptible cell lines of porcine to be tested with CSFV specific
monoclonal antibodies (Anonymous, 1980, 1996; Cay et al., 1989). Two less sensitive tests
are adapted instead for the purpose of reducing labor work:

in situ antigen demonstration

with fluorescent antibody and ELISA targeting specific CSFV antigens. Furthermore,
detection of viral RNA by RT-PCR and following sequencing have become an alternative
(Greiser-Wilke et al., 1998; Hofmann, Brechtbühl, & Stäuber, 1994; Lowings, Ibata,
Needham, & Paton, 1996; Paton, McGoldrick, Belak, et al., 2000).
Serological test is also favored given its rapidness and sensitivity. Virus neutralization
tests are designed for CSF antibody detection in which case serum is mixed with CSF
reference virus so that neutralizing reaction occurs in the presence of antibody. However,
antibodies generated against ruminant pestivirus may cross-react with CSF reference virus
thus a second ruminant pestivirus neutralizing test is required for differentiation. In largescale screening, ELISA tests targeting CSFV specific antibody in serum are more accepted
4

owing to its convenience. Samples tested positive or ambiguous should be processed with
neutralization test again to confirm that they are not fake positive.
There have been many trails to develop CSF vaccines since 1940s. The first attempt
to attenuate CSFV (Baker, 1946; Koprowski, James, & Cox, 1946) was not initially
successful but eventually led to safe and efficacious vaccines. China-strain (C-strain) based
attenuated vaccine is the most widely accepted and used to protect domestic pigs as well
as wild boars from CSF. It is attenuated by adapting in rabbit and can still promote potent
antibody response which protects pigs from virulent CSFV infection as early as five-day
post vaccination. This vaccine is also highly safe and can be given to pregnant animals.
However, such vaccine does not fulfill DIVA (differentiation of infected from vaccinated
animals) criterion since both types of animals exhibit the same pattern of antibody
response.
Therefore, a marker vaccine is needed. E2 subunit vaccine was designed aiming at
only inducing antibody response against viral glycosylated envelope protein E2 in
vaccinated animals, while naturally infected animals generate many more classes of
antibodies including those against viral envelope protein Erns. Therefore, detection of
antibody with high affinity for Erns indicates infection. However, subunit vaccines are less
immunogenic and protection of E2 subunit vaccine is not substantial until 21 dpv.
Additionally, sensitivity of ELISA test designed for detection of Erns specific antibodies is
low. Live attenuated marker vaccine is a more promising option given higher
immunogenicity and potent protection. A successful practice FlagT4G vaccine (Holinka et
5

al., 2014) proven to be capable of inducing effective protection against CSFV challenge as
early as 7 dpv. Two markers are involved in the vaccine: (i) a positive marker, Flagâ
epitope, inserted in E1 glycoprotein, and (ii) a mutation introduced into the WH303 epitope
in E2 glycoprotein (wild type: TAVSPTTLR to mutant: TSFGMDTLR). Positive detection
of antibody against Flagâ epitope and simultaneous negative detection of antibody against
TAVSPTTLR epitope indicates vaccination, while presence of TAVSPTTLR epitope
specific antibodies is interpreted as infection.
Countries with and without endemics of CSF take rather different control policies. The
former adapts a routine of vaccination which protects pigs throughout their economic lives
and only pigs showing clinical signs will be eliminated, but the possibility of virus being
hidden from screening cannot be ruled out. As a result, their meat product is not accepted
for importing by those countries without CSF occurring. In regions where no CSF endemic
exists, governments conduct a stamp-out policy for both herds with infected pigs and
neighboring herds, including epidemiological investigations, clinical diagnosis, tracking
and restriction for movement of live pigs, meat product and vectors with potential
capability of transmitting virus, etc. (Anonymous, 1980; Edwards et al., 2000) Death
caused by CSFV related symptoms actually only accounted for a small proportion, the
majority of pigs were killed out of disease control purpose and such eradication led to
severe economic loss.

1.4 CSFV: Introduction
6

Classical swine fever virus is a spherical enveloped particle of 40 to 60 nm in
diameter, the icosahedral nucleocapsid of which contains 12.3 kb single stranded RNA
genome with positive polarity. The virus belongs to the pestivirus genus of the
Flaviviridae family (Wengler, 1991) and is closely related to other two viruses in the
same genus: bovine viral diarrhea virus (BVDV) and border disease virus (BDV) of
sheep. Viral infectious cDNAs have been successfully produced by some laboratories
(Meyers, Thiel, & Rümenapf, 1996; Moormann, Van Gennip, Miedema, Hulst, & Van
Rijn, 1996; Ruggli, Tratschin, Mittelholzer, & Hofmann, 1996). Four structure proteins:
core protein C, envelope glycoproteins Erns, E1, E2 and seven non-structural proteins: p7,
NS2, NS3, NS4A, NS4B, NS5A, NS5B are encoded in the viral genome (Beer, Reimann,
Hoffmann, & Depner, 2007; Elbers et al., 1996; Meyers & Thiel, 1996). Viral
glycoprotein E2 is the main virulence determinant and is responsible for attachment and
invasion to host cells. Being highly immunogenic, E2 is the main target of neutralizing
antibody and cytotoxic T cell response. Stable existence of virus usually occurs in humid
animal excretion and fresh meat product (Savi, Torlone, & Titoli, 1965), but inactivation
of virus can be easily achieved by damaging viral envelope and nucleocapsid with heat,
detergent, lipid solvent, protease and disinfectants (Edwards et al., 2000).

1.5 CSFV Pathogenesis
Classical swine fever virus preferentially infects endothelial cells, some epithelial
cells, lymphoreticular cells and macrophages (Moennig, 2000). Gestation period infection
7

causes abnormal tissue and organ differentiation and maturation in fetus. Postnatally
infected pigs may develop thrombosis, endothelial damage due to the invasion of virus
into such host cell types. These lesions are usually accompanied with hemorrhage or
petechial bleeding. Pulmonary as well as bronchial epithelial cells infected by CSFV may
lose normal physiological function to a degree where bronchopneumonia occurs. Central
nervous system disorders are presumably resulted by infection of cerebrovascular
endothelial cells and thrombosis given severe vasculitis concomitantly observed with
encephalitis. Depletion of B cells in peripheral blood and lymphoid tissues was reported
in the very late phase of acute infection (Susa, König, Saalmüller, Reddehase, & Thiel,
1992). Antibody response against CSFV may protect pigs up to years or even throughout
entire life (Van Oirschot, 1999). Neutralizing antibody can be detected as early as 11-day
post infection and remain high level up to 100 dpi with data support. In the case of
chronic infection, neutralizing antibody may only be detectable in the few days after 30
dpi (Cheville & Mengeling, 1969; Depner, Rodriguez, Pohlenz, & Liess, 1996).
Prenatally infected pigs which develop persistent viremia hardly generate CSFV specific
antibodies (Van Oirschot, 1999). Postnatal piglets are protected by passive immunity
including maternal antibodies of which the half-life is about two weeks, however, virus is
still capable of replicating and shedding under such circumstance. T cell immunity in
defense of CSFV is comparatively less elucidated.
We realized that the closely related virus BVDV is less virulent than CSFV and when
their E2 protein coding sequences were aligned, significant difference was only observed
8

within the WH303 epitope. Because our previous few attempts to attenuate the CSFV by
arbitrarily introducing mutations into the WH303 epitope ended up being lethal to the
virus, we then only replaced the amino acid within the WH303 epitope of CSFV E2
protein with that of BVDV correspondingly. Starting from the first amino acid alanine,
when all five were mutated (AVSPT to SFGMD), the virus was fully attenuated but it
could still elicit strong and protective immune response in pigs. This phenomenon
indicates the WH303 epitope plays an important role in viral reproduction as well as
pathogenesis.

1.6 Baculovirus/Insect Cell Protein Expression System
Many insect cell lines have been exploited for expression of heterologous proteins
including Bombyx mori, Mamestra brassicae, Spodoptera frugiperda, Trichoplusia ni,
and Drosophila melanogaster among which Spodoptera frugiperda SF9 cell might be the
most commonly chosen one. The ability to undergo posttranslational modification e.g.,
glycosylation, grants insect cells superiority to prokaryotic cell in many recombinant
protein expressions especially those required to be similar to mammalian proteins.
Additionally, the convenience, effectiveness and safety of this approach and the fact that
numerous protein products on market are manufactured in this way may strongly support
the advantages of insect cell protein expression system.
Recombinant baculovirus serves as the vector carrying the foreign genes and
Autographa californica multiple nuclear polyhedrosis virus particularly infects Sf9 cells
9

(Davies, 1994; Shuler & Shuler, 1995). The genome of baculovirus is double-stranded,
circular, supercoiled DNA. The life cycle of wild-type baculovirus includes two forms, the
ODV (occlusion derived virus) and BD (budded virus), however, the recombinant
baculovirus loses the polyhedrin gene which is replaced by a foreign gene of interest. Three
typical phases: early, late and very late phase are involved in wild-type virus infection cycle.
In early phase (0-6 hours), virus attaches to, invades host cell, initiates early viral gene
expression and interferes with host gene expression. During late phase (6-24 hours), viral
DNA is replicated and genes responsible for assembly are expressed to form and release
budded viral particles. Very late phase (24-96 hours) is marked by formation of ODVs and
cell lysis. Recombinant baculovirus does synthesize polyhedrin coat of ODV, but foreign
gene is expressed instead. Cytopathic effects are less noticeable which are merely reflected
by, if grown in T-75 flask, increased cell diameter and enlarged nuclei in the early phase,
cessation of cell growth and dislodgment in late phase as well as cell lysis in very late
phase.

1.7 Significance and Rationale
ELISA targeting CSF specific antibody has been widely used as an approach for CSF
disease screening due to its convenience and high through-put. In particular, countries
without endemics of CSF including the US adapt a non-vaccine policy in the event of
which detection of CSFV specific antibody in serum means elimination of these animals
has to be implemented, leading to tremendous economic loss. However, a marker vaccine
10

and its companion test may exempt healthy vaccinated animals from elimination. In order
to promote the potential wide acceptance and application of a previous CSF live
attenuated marker vaccine candidate, a companion serological test fulfilling DIVA
criterion is urgently needed.
The double-antigenic live attenuated CSF FlagT4G virus (FlagT4Gv) (Holinka et al.,
2014) contains two modifications critical for DIVA purpose one of which is the mutation
in WH303 (mAbWH303) epitope (TAVSPTTLR to TSFGMDTLR) in E2 glycoprotein.
Due to the absence of antibody binding WH303 epitope in vaccinated pigs, CSFV
naturally infected pigs can be discriminated serologically by detecting the presence of
such antibody. Thus, we hypothesize to modify a commercially available ELISA (IDEXX
CSFV Ab Test) to produce a double-competition assay to fulfill this mechanism and
differentiate infection from vaccination.

11

CHAPTER 2
APPROACH, HYPOTHESIS AND SPECIFIC AIMS

12

2.1 Approach to fulfilling DIVA criterion
Here we propose to discriminate CSFV naturally infected from vaccinated pigs using
a double-competition ELISA by detecting a subclass of antibodies which is only present
in sera of infected pigs. Wild type CSFV envelope glycoprotein E2 contains a typical
epitope TAVSPTTLR (amino acid sequence), the immunogenicity of which is rather high
that majority of CSFV specific antibodies generated by infected pigs is against this
epitope. However, a previously developed marker vaccine candidate has a mutation that
epitope TAVSPTTLR is replaced by TSFGMDTLR, leading to vaccinated animals
lacking of antibodies against TAVSPTTLR epitope. By incubating sera with a
recombinant peptide termed E2T4G that is identical to the wild type E2 protein except for
the absence of WH303 epitope, antibodies generated by infected pigs remain dissociative
thus being detected by the IDEXX ELISA.

2.2 Hypothesis
The failure to distinguish between naturally infected and FT4G vaccinated pigs using
the commercially-available IDEXX ELISA is due to the inability of conjugates to bind in
the presence of irrelevant antibodies against non-WH303 epitopes in E2 protein.
Recombinant protein E2T4G can sequester irrelevant antibodies and enrich anti-303
antibodies, thus making the difference distinguishable.
2.3 Specific aims
1. Biosynthesize genetically modified viral envelope glycoprotein E2 (E2T4G) with
13

baculovirus/insect cell protein expression system.
2. Interfere commercial ELISA with E2T4G to enrich antibodies that are merely
present in sera from naturally infected pigs.

14

CHAPTER 3
SPECIFIC AIM 1:
BIOSYNTHESIS OF RECOMBINANT
VIRAL ENVELOPE GLYCOPROTEIN E2

15

3.1 Introduction
Baculovirus/insect cell protein expression system has been long practiced to
successfully produce recombinant proteins. In this research, recombinant baculovirus
encoding genetically modified viral envelope glycoprotein E2 (E2T4G) was constructed,
amplified, titrated and stocked at 4 ℃. Sf9 cells were grown firstly in a monolayer then
suspension culture was adapted for the purpose of reducing consumption, labor work,
contamination risk and increasing cell viability. The recombinant protein E2T4G is not
secretory but loses the transmembrane domain so that extraction is simply by adding lysis
buffer and high-speed centrifugation. The loss of such transmembrane domain will also
lead to a decreased molecular weight compared to the approximate 55 kDa of the wild
type viral E2 protein. Anti-his-tag Western blot was performed to identify the presence of
E2T4G in clarified cell lysate followed by cobalt column purification, desalting, BCA
assay and on-chip electrophoresis. Protocols and conditions had been explored to achieve
high protein expression and to reduce unnecessary loss during extraction and purification.

3.2 Materials and methods
Cell culture

Sf9 cells were purchased from Invitrogenâ and preserved at -80℃ at a

concentration of 1*106 cell/ml. Gibco Grace’s Medium (1X) was supplemented with 20%
heat inactivated FBS (RMBI). Gentamicin (SIGMA) was added to a final concentration
of 0.05 mg/ml. To initiate an adherent culture, Sf9 cells were thawed at room temperature
and mixed with 10 ml of growth media before centrifugation for 5 min at 1000 rpm.
16

Cellular pellet was suspended with 6 ml of media and transferred to a T-25 flask, growing
at 27℃. 24 hours after inoculation, media was replaced with fresh ones to remove any
remaining DMSO. Cells were scraped down and transferred to a T-75 flask when
confluency reached 100% and volume of medium used in a T-75 was 15 ml. To start a
culture in suspension, Sf9 cells were taken from a T-75 flask with 100% confluency and
added to a 250-ml conical glass flask to reach a concentration of 1*106 cell/ml in a total
volume of 30 ml. 300 ul pluronicâ (GIBCO, 10%) was added to protect cells from shear
force at the shake speed of 125 rpm. Growth state was monitored daily by counting using
hemocytometer and trypan blue staining. Culture was expanded to a 500-ml conical flask
under the circumstance that viability was no lower than 90% and concentration reached
2*106 cell/ml.

Baculovirus construction

Recombinant baculovirus was constructed on the basis of

site-specific recombination with the Gatewayâ Technology of Invitrogen. DNA sequence
of recombinant viral envelope glycoprotein E2 (E2T4G) was synthesized into a bacmid
containing two att recombinant sites by GENEWIZ. Recombination was performed
following manufacturer’s protocol (BaculoDirect™ Baculovirus Expression System,
Invitrogen). Virus passage III was titrated and stocked at 4 and -80℃.

Infection and harvest

Sf9 cells in monolayer were infected with a MOI of 0.1~5

when confluency reached 90% and were scraped down at 7 dpi when cell viability
17

decreased to approximately 80%. Infection in suspension was initiated when cell
concentration was over 2*106 cell/ml and was terminated when cell viability dropped
below 80%. Cell suspension was centrifuged at 3200 rpm for 5 min. Supernatant
containing virus was collected for future infection and cellular pellet was washed twice
with PBS (1X, GIBCO) before 10 ul of RIPA cell lysis buffer (Thermo) was added per
1*106 cells. After 10 min on-ice incubation, 10 min centrifugation at 13200 rpm was
performed to collect clarified cell lysate, stored at -20℃.

Qualitative and quantitative test

Western blot was performed to detect the presence

of recombinant protein in both whole cell lysate and clarified cell lysate. Standard
molecular weight marker, Bis-Tris gel, MES SDS running buffer, transfer buffer, PVDF
membrane, anti-his primary antibody (C-term) as well as chemiluminescent
immunodetection kit were purchased from Invitrogen. Image developing was done with
BIO-RAD ChemiDoc™ Imaging System with exposure time starting at 30s to as long as
300s. Clarified cell lysate samples showing high expression were purified and desalted
following manufacture’s protocol with HisPur™ Cobalt Purification Kit (Thermo) and
Zeba™ Spin Desalting Column (Thermo). Western blot was also performed with purified
and desalted samples. Concentration of total proteins was measured by Pierce BCA
Protein Assay (Thermo) and the percentage of E2T4G was determined by Agilent High
Sensitivity Protein 250 Kit (Agilent Technologies) thus the exact concentration of E2T4G
could be calculated.
18

3.3 Results
3.3.1 Cell culture in Monolayer and Suspension
Unlike most mammalian cells, Sf9 cells adhere weakly to T-25/75 flasks and get
dislodged easily. It is normal that some floating cells could be observed under inverted
microscope especially when flask was moved, rocked or the confluency of monolayer
increased above 100%. However, too many floating cells in the event of overnight
incubation after thawed and transferred to T-25 flask or confluency lower than 100%, still
indicate unhealthy cell state. Cells of low passage number (< p.20) replicated faster,
usually taking three days to reach 100% in a T-25 flak after seeding at a number of 1*106
and two to three days to fully grow in a T-75 flask after splitting at a ratio of 1/3. Cells of
high passage number (> p.26) took longer to multiply, nearly twice of what was needed
by those of low passage number. Based on practice, at 100% confluency the total number
of cells in a T-75 flask fluctuated around 4.5*107 and corresponding concentration was
around 3*106 cell/ml, in a volume of 15 ml of media. Counting with hemocytometer for
culture in monolayer required cells to be scraped down, therefore shear force applied to
cells decreased viability to approximately 93% and clumps of cells led to inaccuracy in
calculation.
Culture in suspension was then adapted to replace growing with T-75 flasks due to
many disadvantages of the latter. Cells grew to 100% confluency in a T-75 flask was still
needed to initiate culture in a 250-ml conical glass flask at a concentration of 1*106
19

cell/ml in a total volume of 30 ml of grow media. Cells with low passage number
multiplied quickly and took two days to reach 2*106 cell/ml when they need to be
transferred to a 500-ml flask where an additional two days were usually necessary for
growing back to 2*106 cell/ml. Cell viability observed was higher than that in monolayer,
being around 99%-100%. A typical growth curve is provided in figure 1.

3.3.2 Infection with Recombinant Baculovirus
Cells growing in monolayer were infected when confluency reached 90% by directly
adding virus stock or medium containing virus particle which was collected from a
previous protein production with a MOI ranging from 0.1 to 5. No conspicuous
cytopathic effect could be observed in the first two to three-day post infection except that
nuclei might appear to be enlarged due to virus replication. The most obvious cytopathic
effect is elevated dislodging of cells from monolayer compared to non-infected group,
occurring as early as 3 dpi and culminating at 7 dpi when more than 80% cells floated in
the medium. Harvest was done at 3/4/5/6/7/8 dpi and only cell pellets were kept. Grow
media were discarded after centrifugation. Proteins were extracted by adding lysis buffer
to cell pellets and both cell lysate and clarified cell lysate were tested by Western blot
(WB) for the expression of recombinant. The highest expression of E2T4G was achieved
at 7 dpi with cell viability around 85% and a total concentration around 2*106 cell/ml.
Infection in suspension was done with the same MOI by directly adding virus stock
or medium from a previous infection. After infection, cell concentration still increased
20

from 2*106 cell/ml to approximately 4*106 cell/ml during the first three days. Significant
decrease in viability was not observed until 3 dpi when 96% were alive following by 90%
at 4 dpi and 80% at 5 dpi. A large decrease in viability from 80% to 40%-60% would be
observed if not harvested which would cause a tremendous loss of target protein. A
typical growth curve is shown in figure 2.
For both of the two growths, non-typical growth state/curve inconsistent with the
description above was also observed, reflected by higher cell density (> 2*106 cell/ml) at
expansion or infection time point or higher viability (> 80%) at harvest day, which might
be attributed to different cell passages, inaccurate cell counting and temperature
fluctuation.
Comparison of different parameters between culture in monolayer and suspension is
shown in Table 1. Advantages of production with growth in suspension include reduced
consumption of medium, flasks, labor work and risk of contamination as well as
increased cell viability.

3.3.3 Protein Extraction, Purification and Identification
Western blot was performed according to manufacturer’s protocol. Bands of
molecular weight marker and target protein were recognizable as early as 30-second
exposure with ChemiDocTM Imaging System (BIO-RAD). Band of target protein E2T4G
lies around 50 kDa instead of 55 kDa as the case of wild type E2 protein. Such reduction
in size might be attributed to the deletion of transmembrane domain. Different from
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clarified cell lysate, whole cell lysate exhibited an additional band around 40 kDa. These
peptides also had his-tag but were of different molecular weight, indicating more than
one version of E2T4G was synthesized which could be variously glycosylated proteins or
other non-specific proteins. Some E2T4G appeared to lost during centrifugation too,
leading to a slightly weaker band corresponding to that of whole cell lysate (figure 3A).
It was observed that whole cell lysate was much more viscous than clarified cell
lysate, as a result of which the former was extremely difficult to load into the gel well for
WB and band shown after image developing, though intensity being higher, was not as
sharp compared to clarified lysate. An explanation is that high concentration of protein
contributes to the viscidity of sample.
Purified samples lost considerable proportion of target protein, reflected by much
weaker band in WB image. Proteins were eluted from purification column three times
with elution 2 usually having the strongest band. Desalting was performed to further
increase purity but a conspicuous loss of protein was unavoidable (data not shown).
BCA assay was done to measure the concentration of total proteins in purified and
desalted products. Elution 1 of purified sample shown the highest concentration, with
elution 2, 3 and desalted product showing a gradual decrease. Data are provided in table
2. Given the fact that non-specific proteins were synthesized and they might all contain a
‘his-tag’, in order to determine the comparatively accurate percentage of E2T4G, protein
on-chip electrophoresis was performed. Proportion of each protein component was
readable with bio-analyzer. By comparing to a highly purified positive control which was
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a different recombinant viral E2 produced using the same expression system is our lab
previously. Considering both the concentration of total proteins in the solution and the
percent of E2T4G, its actual concentration could be calculated (table 2). Schematic
picture of E2T4G is shown in figure 5.
A typical result of on-chip protein electrophoresis is shown in figure 4. Molecular
weight of a band cannot be simply determined based on ladder because the ladder is
computer generated and only represents the migration speed. Instead, by comparing to the
positive control, if similar pattern was observed, the sample would be considered of good
quality. Each peak represents one protein component and height of the peak indicates the
relative amount, which means samples exhibiting few and high peaks and were purer.
Elution 1, 2 and 3 all contained many different kinds of non-specific proteins and the
proportion believed to be E2T4G is respectively 15%, 21.6% and 20% (table 2, figure 4).
Desalting process further excluded non-specific proteins but recovery was low, therefore
desalted elution 3 had higher purity (figure 4) but almost 60% of protein was lost (table
2).

3.4 Discussion
Previous research and manufacturer’s protocol validate the feasibility of adapting
suspension culture for Sf9 cell growth. The exploration on growth conditions took
months and ultimately exhibited conspicuous superiority to monolayer culture (table 1). A
typical round of production using adherent culture required thirty T-75 flasks but actually
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another fourteen flasks were needed to finally generate thirty. Considering 15 ml growth
media was added to each flask, an entire volume of 660 ml media was needed. Therefore,
culture in suspension is much more efficient and largely reduces labor work,
consumptions and risk of contamination. In addition, without shear force applied to cells
when they were scraped down, those growing in suspension exhibited much higher
viability, nearly 100%, which was desired for protein expression. Some disadvantages of
suspension culture pointed out by previous research include forming of clumps and
potential risk of contamination due to growth in conical flask. However, clumps of cell
were hardly observed and contamination never occurred in my practice.
Infection was done at a low MOI, 0.1-5 as recommended by manufacture. In this
research, media containing viral particles was collected and saved for next round of
infection. If good protein expression was gained from such infection with this virus stock,
it would also be used for following several rounds of production. Viral titration was not
performed for these virus stocks due to unsuccessful attempts, mostly unsuccessful
staining using neutral red. However, manufacturer’s protocol mentions that such virus
stock typically has a pfu of 5*107 to 1*108 per milliliter. Given the number of cells
(2*108) and volume of virus (500 ul) added in suspension when infection was initiated,
the MOI I actually ended up using should be around 0.125-0.25 which fell into the
recommended range. Moreover, the growth curve was consistent with this low MOI,
reflected by a slight increasing in density and prolonged high viability within three to
four days after infection.
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Though designed to lose the transmembrane domain, the recombinant E2T4G was
not easily extracted and recovered from cells. Cell lysis buffer was used in our research to
break Sf9 cells and release protein of interest in which case it should be dissociative.
However, shown by Western blot, samples lost large proportion of E2T4G after
centrifugation, indicating much was associated with cell debris. Incubation time with
lysis buffer was increased as well as repetitive freezing and thawing was adapted for the
purpose of breaking potential linkage between E2T4G with cell debris, but no substantial
improvement was observed. Cellular pellet was washed with ice cold PBS and
centrifugation after adding lysis buffer was performed at 4 ℃ laboratory with the
intention of protecting E2T4G from degradation. Still, no apparent increase in protein
expression was achieved.
Given that recombinant E2T4G undergoes glycosylation, more than one version of
proteins were probably synthesized. Based on western blot, whole cell lysate shown an
additional band of slightly lower molecular weight which disappeared in clarified cell
lysate. Bio-analyzer shown that purified product elution 3 lost many non-specific proteins
after desalting. Both the band disappeared in clarified cell lysate and peaks lost in
desalted elution 3 might be E2T4G with different degrees of glycosylation.
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Table 1. Comparison of Culture in Monolayer and in Suspension.
CATEGORIES

MONOLAYER

SUSPENSION

Number of T-25 flask

1

1

Number of T-75 flask

44

4

Volume of media

660

300

Number of cells (harvested)

8*108

10*108

Cell viability (prior to infection)

95%

100%

References: (1) The number of cells that can be produced in each batch of production in
suspension is approximately equivalent to 1/3 of that in T-75 flasks. (2) Numbers were
selected from samples with typical growth state/curve. Exceptions were not included
(data not shown).
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Table 2. Quantitation of Purified and Desalted Sample.
CATEGORY

ELUTION 1

ELUTION 2

ELUTION 3

DESALTED

270

244

97

37

15

21.6

20

27

40.5

52.7

19.4

10

Concentration
of total protein
(ng/ul)
% Percentage
of E2T4G
Concentration
of E2T4G
(ng/ul)
References: (1) Elution 3 was desalted and recovery rate was significantly lower than
expected, though purity increased. No desalting treatment was done for elution 1 or 2.
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Concentration (*106 cells/ml)

A

3

2.5
2

1.5
1

0.5
0
0

24
Hour
Alive

B

Dead

48
Total

% Cell Viability

100
80
60

40
20
0
0

24
Hour

48

Figure 1. Growth curve of Sf9 cell in suspension (250-ml conical flask). (A)
Concentration of living/dead/total cells in suspension. X-axis: hour post seeding, Y-axis:
cell density (*106 cells/ml). (B) Cell viability based on trypan blue staining. X-axis: hour
post seeding, Y-axis: % cell viability.
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Concentration (*106 cells/ml)

A

5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
0

24

48
Alive

B

72
96
Hour
Dead

120

144

168

144

168

Total

% Cell Viability

100
80
60
40
20
0

0

24

48

72
96
Hour

120

Figure 2. Growth curve of Sf9 cell in suspension after transferred to a 500-ml conical
flask and infection. Infection was initiated at 72-hour after transferred by directly adding
virus stock or medium containing virus collected from a previous round of production.
(A) Concentration of living/dead/total cells in suspension. X-axis: hour post seeding, Yaxis: cell density (*106 cells/ml). (B) Cell viability based on trypan blue staining. X-axis:
hour post seeding, Y-axis: % cell viability.
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Figure 3. Western blot of whole, clarified cell lysate and purification product. Exposure
time was set to be 300 seconds. (A) Protein was extracted from cells growing in
suspension. Lane 2 shows whole cell lysate, the larger band being approximately 50 kDa
and the other being slightly below 40 kDa. Lane 1 shows the corresponding clarified cell
lysate, with the same molecular weight as the larger band in lane 2. (B) Clarified cell
lysate from another round of production with adherent culture was purified. Lane 1 to
lane 3 represents elution 1 to elution 3 of purified product respectively, with the same
weight around 50 kDa.
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Figure 4. On-chip protein electrophoresis revealed a variety of proteins in purified and
desalted products. (A) Gel-like picture. Ladder does not show molecular weight but
exhibits the migration speed. Duplicates were made for each sample. E1: elution 1, E2:
elution 2, E3: elution 3, P: positive control and D: desalted elution 3. (B) Purified product
elution 1 still contained many non-specific proteins reflected as multiple peaks. The peak
considered to be E2T4G is pointed out with an arrow. (C) Elution 2 contained a slightly
higher percentage of E2T4G reflected by a higher peak. (D) In elution 3, relatively fewer
non-specific proteins were present. The proportion of E2T4G was similar to elution 2. (E)
Desalted elution 3 contained conspicuously fewer non-specific proteins as well as a much
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higher percentage of E2T4G. (F) Positive control used here is a different kind of
recombinant viral E2 protein produced in our lab previously using the same expression
system. The purity was apparently higher than any of other E2T4G samples. (G) A typical
running pattern of ladder with seven peaks, indicating successful on-chip electrophoresis.
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Figure 5. Comparison of E2 and E2T4G. The only difference in recombinant viral
glycosylated envelope protein E2 from wild type one is the mutation in WH303 epitope,
TAVSPTTLR to TSFGMDTLR (amino acid sequence). Polyclonal antibodies generated
by infected pigs contain those with high affinity to TAVSPTTLR epitope but in
vaccinated pigs such antibody is missing. Antibodies against other epitopes should be the
same in both naturally infected and vaccinated pigs.
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CHPATER 4
SPECIFIC AIM 2:
MODIFICATION OF A COMMERCIALLY AVAILABLE ELISA
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4.1 Introduction
ELISA detecting the presence of antibody in serum against CSFV envelope
glycosylated protein E2 has been widely used for high-throughput screenings within
herds due to its convenience, high sensitivity and specificity. IDEXX CSFV Ab Test is a
commercially available ELISA kit designed for accurate detection of CSFV specific
antibodies in serum. It is widely accepted and more importantly it is used by the USDA
for screening and surveillance. CSFV glycosylated envelope protein E2 is coated on the
plate by manufacture and serum will be incubated in the well either for two hours or
overnight. Positive serum control comes with the kit and will be treated in the same way.
Enzyme linked monoclonal antibody (anti-E2) can be added to the well after washing
away sera. Polyclonal antibody in pig sera against E2 binding to E2 in the plate will
block secondary monoclonal antibody from binding, thus exhibiting an inhibition rate.
Samples giving inhibition rate higher than 40% will be considered as infection. In this
research, recombinant E2T4G was co-incubated with pig sera in the plate with the
intention of sequestering irrelevant antibodies (anti-E2 but not anti-303) and enriching
anti-303 antibodies. In this setting, inhibition rates higher than 40% would still be
considered as infection but lower ones would be regarded as vaccination. Schematic
pictures are shown in figure 6. However, we had another expectation that in the presence
of E2T4G, the inhibition rate of serum samples from a FT4G vaccinated animal would
still be higher than 40% but significantly lower than in the absence of E2T4G.
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4.2 Materials and Methods
Vaccination and challenge

Sera tested in this research were stocked at -80℃ freezer.

Animals were previously allocated into three groups with 4 pigs in each. Group 1 and 2
were inoculated with 105 TCID50 FlagT4v (Holinka et al., 2009) intranasally (IN), and
group 3 was made a mock of infection. Pigs in group 1 and group 2 were challenged IN
with 105 TCID50 CSFV Brescia strain (BICv) (Risatti, Borca, et al., 2005) at 3 DPI and
28 DPI respectively, along with animals in group 3. Daily clinical signs including body
temperature were monitored throughout the experiment as previously described (Risatti,
Holinka, et al., 2005). Peripheral blood was collected at different time points postvaccination and post-challenge from the anterior vena cava in EDTA-containing tubes
(Vacutainer). Samples were preserved at -80℃ freezer for subsequent use. All
experiments were performed in Plum Island Animal Disease Center (NY).

ELISA

IDEXX CSFV Ab Test Kit was used for the detection of CSFV E2 specific

antibody in animal sera. Test was done as recommended by manufacturer’s instructions.
25 ul of the sample diluent and 25 ul of E2T4G were added to all wells first, then 50 ul
positive or negative control or serum samples were added respectively. Plate was
incubated for 2 hours. Each well was added with 100 ul conjugated after rinse using 300
ul of wash solution. Incubation of 30 min was required before addition of substrate.
Reaction was allowed to develop for 10 min then absorbance of the samples and controls
was measured at 450 nm with Bio Tek ELx 808 ELISA Reader. Negative control mean =
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(NC A450 + NC2 A450)/2, positive control mean = (PC A450 + PC A450)/2, blocking
percentage (rate of inhibition) = (NCmean A450 - Sample A450)/NCmean A450*100.
Sample with a calculation of blocking percentage ≥ 40% was considered positive while
≤ 30% was considered negative. All tests were performed in Plum Island Animal
Disease Center (NY).

4.3 Results
4.3.1 E2T4G decreased inhibition in the case of vaccination instead of infection.
Desalted elution 3 containing E2T4G was co-incubated with sera in ELISA plate.
Wash steps and incubation of enzyme-linked secondary antibody were performed
according to manufacturer’s protocol. Readings of ELISA reader was calculated for
percentage of inhibition (figure 6) and column chart is shown in figure 7. Sera from four
vaccinated (FlagT4v) pigs at 28 DPI revealed an inhibition rate ranging from 45% to
62%, while in the addition of E2T4G a 10% decrease was observed and one pig (No. 10)
exhibited inhibition lower than 40%. Sera collected at 42 DPI from six vaccinated pigs
had an obviously higher inhibition ranging from 68% to 78% mostly attributed to further
developed antibody response. Co-incubation of E2T4G led to an average decrease in
inhibition of 15% but one pig (No. 16) shown no more than 5% decrease. The lowest
inhibition rate was 52% (pig No. 13). After challenging with CSFV Brescia strain, pigs
generated antibodies against WH303 epitope which was enriched in the presence of
E2T4G and led to a high inhibition rate. Consistent to this, sera taken from four pigs at
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17-day post-challenge all exhibited high inhibition ranging from 72% to 88% regardless
of addition of E2T4G. Our observation is actually consistent with our second expectation
which is that in the presence of E2T4G, serum samples would have a lower inhibition
rate than in the absence of E2T4G but such rate would still be higher than 40%. Because
the serum samples taken from infected animals exhibited a very similar inhibition rate
irrespective of the addition of E2T4G, while serum samples form vaccinated pigs showed
clearly different inhibition rates depending on E2T4G, we conclude that adding the
recombinant viral E2 protein E2T4G can confer DIVA capability to the commercial
IDEXX ELISA Kit.

4.4 Discussion
The modification we made to the commercially available IDEXX ELISA exhibited
capability of differentiating CSFV naturally infected pigs from vaccinated ones.
However, the inhibition rate of infected and vaccinated cohorts did not significantly differ
and compared to manufacture’s cutoff line 40%, the 10%-15% decrease in inhibition did
not substantially distinguish between positive and negative samples. We attribute the
unexpected low percentage of inhibition to suboptimal ELISA protocol as well as
insufficient amount and purity of recombinant glycoprotein E2T4G.
ELISA is now a widely used tool for the purpose of sensitive, specific and
convenient detection which, however, requires much experience and well controlled
experiment conditions. We attempted to increase inhibition rate by pre-incubating serum
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with recombinant protein or using different combinations of diluted serum and E2T4G,
but no significant improvement was observed (data not shown). Nevertheless, there are
more conditions remaining to be adjusted including temperature, incubation time, volume
of each reagent and serum or E2T4G of higher or lower dilution rate. Additionally, given
the relative low concentration of recombinant E2T4G in the reaction, it will not be
surprising if the anti-WH303 antibodies cannot be thoroughly adsorbed and precipitated.
Despite the insignificant difference in inhibition percentage, our exploration on
making the commercial ELISA fulfill DIVA criterion is successful and our strategy is
promising for the development of such DIVA ELISA. With this being said, more work
will have to focus on both optimizing ELISA protocol and increasing concentration and
purity of recombinant E2T4G. In order to obtain high amount of purified E2T4G, efforts
can be made on redesigning protein coding sequence, improving cell culture
methodology, adjusting protein extraction and purification process and utilizing other
protein biosynthesis systems.
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Antibody with affinity for the TAVSPTTLR epitope
Antibody with affinity for the TSFGMDTLR epitope
Antibody with affinity for other epitopes within E2
Antibody with affinity for other epitopes within E2
Enzyme linked secondary antibody

Figure 6. Schematic picture of traditional and modified ELISA. (A) Polyclonal antibodies
in serum samples from an infected pig, including those with high affinity for
TAVSPTTLR epitope, bind to E2 at the bottom, exhibiting a high inhibition rate. (B)
Polyclonal antibodies in serum samples from a vaccinated pig, those against
TAVSPTTLR epitope not included, can also bind to E2, exhibiting high inhibition. (C) In
the addition of E2T4G, in serum samples from an infected pig, only antibodies against
TAVSPTTLR epitope can block E2. (D) Addition of E2T4G sequesters antibodies in in
serum samples from a vaccinated pig, thus showing a low/no inhibition rate.
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Figure 7. Addition of E2T4G decreased percent of inhibition in the case of vaccination
instead of infection in preliminary trails. Control group: ELISA run without addition of
E2T4G, test group: ELISA run in the presence of E2T4G. (A) Sera were taken from four
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vaccinated pigs at 28 DPI. Addition of E2T4G decreased inhibition by 12%, 7%, 13%
and 8% respectively. (B) Sera were collected from another six vaccinated pigs at 42 DPI.
Addition of E2T4G decreased inhibition by 17%, 17%, 15%, 14%, 15% and 6%
respectively. (C) Sera were taken from pigs at 17-day post-challenge with CSFV Brescia
strain. Addition of E2T4G did not result in significant difference in inhibition, only 2%,
4%, 2% and 2% respectively.
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CHPATER 5
CONCLUSION
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5.1 Conclusion
The production of recombinant CSFV glycoprotein E2 through baculovirus/insect
cell protein expression system is successful. Growing and infecting Sf9 insect cells in
suspension is proved in my trial to be more effective, material-saving and significantly
less labor-intensive compared to adherent culture. The recombinant protein E2T4G was
obtained and quantitated after protein extraction and purification.
The modification on commercially available ELISA, IDEXX CSFV Ab Test, meet
our expectation as the difference in inhibition rate between infected and vaccinated pigs
was clear and distinct.
In conclusion, the specific aim 1 of this research is successfully achieved and the
result of specific aim 2 potently supports the described strategy for the future
development of a CSFV DIVA ELISA for the FT4G vaccine candidate.
More work remains to be done including achieving higher concentration and purity
of the recombinant protein E2T4G as well as improving the ELISA protocol. In order to
produce E2T4G of better quality, codon optimization, different culture conditions,
different extraction and purification procedures can be tried. In terms of improving
ELISA protocol, more conditions can be explored: the order of reagents added to the
ELISA plate, pre-incubation of E2T4G with serum samples, different incubation time of
E2T4G with serum samples, different concentrations of E2T4G, different dilutions of
serum samples, serum samples collected at different dpi.
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SUPPLEMENTARY DATA
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Supplement 1. Nucleotide sequence of recombinant CSFV glycoprotein E2.
Mellitin-E2-T4G-deltaTMR-6XHis:
ggatcc1ATGAAATTCTTAGTCAACGTTGCCCTTGTTTTTATGGTCGTATACATTTCTTACATCTATGCGCG
G2CTAGCCTGCAAGGAAGATCACAGGTACGCTATATCAACAACCAATGAGATAGGGCTACTTGGGGCCGAAG
GTCTCACTACCACCTGGAAAGAATACAACCACAATTTGCAACTGGATGATGGGACCGTCAAGGCCATCTGC
ATGGCAGGTTCCTTTAAAGTCACAGCACTTAATGTGGTTAGTAGGAGGTATCTGGCATCATTACATAAGGA
CGCTTTACCCACTTCCGTGACATTCGAGCTCCTGTTCGACGGGACCAGCCCATTGACCGAGGAAATGGGAG
ATGACTTCGGGTTCGGACTGTGTCCGTATGATACGAGCCCTGTAGTCAAGGGAAAGTACAACACAACCTTG
TTGAATGGTAGTGCATTCTACCTAGTTTGCCCAATAGGGTGGACGGGTGTTATAGAGTGCACGagtttcgg
aatggatACTCTGAGA3ACAGAAGTGGTAAAGACCTTCAGAAGAGAGAAACCCTTTCCGTACAGAAGGGATT
GTGTGACCACTACAGTGGAAAATGAAGATCTATTCTACTGTAAATGGGGGGGCAATTGGACATGTGTGAAA
GGTGAACCAGTGACCTACACGGGGGGGCCAGTAAAACAATGCAGATGGTGTGGCTTCGACTTCAATGAGCC
TGACGGACTCCCACACTACCCCATAGGTAAGTGCATTTTGGCAAATGAGACAGGTTACAGAATAGTGGATT
CAACGGACTGTAACAGAGATGGCGTTGTAATCAGCACAGAGGGGAGTCATGAGTGCTTGATTGGTAACACA
ACTGTCAAGGTGCATGCATTAGATGAAAGACTAGGCCCTATGCCATGCAGGCCTAAGGAGATCGTCTCTAG
TGCGGGACCTGTAAGGAAAACTTCCTGTACATTCAACTACGCAAAAACTCTGAGGAACAGGTATTATGAGC
CCAGGGACAGCTATTTCCAACAATATATGCTCAAGGGCGAGTATCAGTACTGGTTTGATCTGGATGTGACC
GACCGCCACTCAGATTACTTCGCAGAAcaccatcaccatcaccattaa4gaattc1

Reference: 1. Two restriction enzyme recognition sites (BamH1: GGATCC, EcoR1:
GAATTC). 2. Coding sequence of signal peptide for secretion. 3. Mutagenized WH303
epitope coding sequence. 4. (6x) His-tag coding sequence.
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Supplement 2. Amino acid (one letter) sequence of recombinant CSFV glycoprotein
E2.
MKFLVNVALVFMVVYISYIYAR1LACKEDHRYAISTTNEIGLLGAEGLTTTWKEYNHNLQLDDGTVKAICMA
GSFKVTALNVVSRRYLASLHKDALPTSVTFELLFDGTSPLTEEMGDDFGFGLCPYDTSPVVKGKYNTTLLN
GSAFYLVCPIGWTGVIECTSFGMDTLR2TEVVKTFRREKPFPYRRDCVTTTVENEDLFYCKWGGNWTCVKGE
PVTYTGGPVKQCRWCGFDFNEPDGLPHYPIGKCILANETGYRIVDSTDCNRDGVVISTEGSHECLIGNTTV
KVHALDERLGPMPCRPKEIVSSAGPVRKTSCTFNYAKTLRNRYYEP RDSYFQQYMLKGEYQYWFDL
DVTDRHSDYFAEHHHHHH3

Reference: 1. Additional hydrophobic signal peptide for secretion. However, the
recombinant E2 lacks terminal hydrophobic amino acid sequence (about 32 aa, not
shown) which is believed to be the transmembrane domain. 2. Mutagenized WH303
epitope. Five altered amino acids are S, F, G, M and D which in wild type E2 correspond
to A, V, S, P and T respectively. 3. Six-histidine tag for detection with Western blot.
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